The mechanism of the additive effect is not clear but our data suggest that within the ErbB2 normal DCIS samples the additional efficacy may be due to an up regulation in Notch1 activity, leading to a more effective inhibition when both ErbB1 and Notch inhibitors are used. Here, EGFR is linked to ductal breast carcinoma in situ.